Last updated: March 13, 2026
What is the drug associated with NDC 49702-0222?
NDC 49702-0222 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy for spinal muscular atrophy (SMA) in pediatric patients under two years old. Approved by the FDA in May 2019, Zolgensma is designed to deliver a working copy of the defective SMN1 gene via a one-time intravenous infusion.
What is the current market landscape?
Market Size and Patient Population
- Prevalence: SMA affects approximately 1 in 10,000 live births, with an estimated 350 new cases per year in the U.S.
- Target Population: Predominantly infants and children under two years, with potential expansion to older children and adults in emerging indications.
- Market Penetration: As of 2023, approximately 25-30% of eligible patients in the U.S. have received Zolgensma, constrained by costs and access.
Competitive Environment
- Primary competitor: Spinraza (nusinersen, NDC 55513-103-01), an intrathecal injection approved in December 2016.
- Other emerging therapies: Evrysdi (risdiplam), approved in August 2020, administered orally.
- Pricing competition is limited; Zolgensma commands a premium due to its one-time administration and curative potential.
Adoption Factors
- Early diagnosis via newborn screening increases uptake.
- Cost and reimbursement policies impact patient access.
- Long-term efficacy data solidify its position as a potential curative option.
What are the price projections?
Current Pricing
- List Price: Approximately $2.1 million per treatment course in the U.S., making it one of the most expensive drugs.
- Reimbursement: Many payers negotiate discounts, with actual net prices estimated around $1.5 million.
Price Trends
- Price Stability: No significant reduction observed since approval; discounts and rebates influence actual costs.
- Potential for Decrease: Not expected in the near term due to high fixed manufacturing costs, although competitive pressures from emerging therapies may influence future pricing.
- Value-based Agreements: Payers are increasingly seeking outcomes-based contracts to mitigate financial risk.
Price Projections in the Next 5 Years
| Year |
Estimated List Price |
Estimated Net Price |
Key Factors |
| 2023 |
$2.1 million |
~$1.5 million |
Market penetration, manufacturing costs, payer negotiations |
| 2024 |
Stabilizes |
Slight decrease possible |
Payer negotiations, potential discounts, new competitors |
| 2025 |
Maintains stability |
No significant change |
Limited pipeline impact, high fixed costs |
| 2026 |
Similar pricing |
Slight discounts possible |
Market maturity, healthcare policy shifts |
| 2027 |
Slight reduction |
Continued stable or declining |
Value-based contracting, increased competition |
Payer and Policy Impact
- Reimbursement models increasingly favor outcome-based agreements.
- Medicaid and private insurers leverage negotiated rebates.
- Legislative pressures may influence future drug pricing.
What is the market outlook?
- The treatment market for SMA is expected to grow at a compound annual growth rate (CAGR) of approximately 10% over the next five years, driven by expanded newborn screening and earlier intervention.
- Patent life extends until 2033, providing long-term market exclusivity.
- Production capacity constraints could influence supply and pricing dynamics.
Key challenges to pricing and market growth
- Cost-effectiveness debates: Payers scrutinize high costs against clinical benefits.
- Access barriers: Distribution logistics of gene therapy require specialized centers.
- Long-term efficacy data: Limited real-world data impacts payer confidence.
Summary
| Aspect |
Details |
| Year of FDA approval |
2019 |
| Approved indications |
SMA in children < 2 years |
| Estimated U.S. market size |
$1.85 billion (2023), growing with increased adoption |
| Competitive position |
Dominates high-cost, one-time gene therapy segment |
| Price trajectory |
Stable with slight downward pressure; no significant reduction expected in the near term |
Key Takeaways
- NDC 49702-0222 corresponds to Zolgensma, a pioneering gene therapy for SMA.
- It commands a high list price (~$2.1 million), with actual net prices around $1.5 million.
- The market is influenced by improving diagnosis rates, reimbursement negotiations, and emerging competitors.
- Long-term market growth remains positive, though price stability is likely due to manufacturing costs and regulatory exclusivity.
- Payers are increasingly pursuing outcome-based agreements to address high treatment costs.
FAQs
1. Will the price of Zolgensma decrease in the future?
Potentially, driven by market competition, patent expirations, and outcome-based agreements, but no immediate reductions are expected.
2. How does Zolgensma compare to Spinraza in value?
Zolgensma offers a one-time treatment with potentially lifelong benefits, whereas Spinraza involves ongoing injections. Its high upfront cost is offset by potential long-term savings and efficacy.
3. Is there a plan for broader indications?
Research is ongoing to expand use to older patients and different SMA types, which could impact market size and pricing.
4. What are the reimbursement challenges?
High treatment costs lead to negotiations, rebates, and outcome-based contracts, complicating payer reimbursement strategies.
5. How do manufacturing costs influence pricing?
Complex production processes and low economies of scale sustain high prices despite market growth.
References
- FDA. (2019). FDA approves first gene therapy for spinal muscular atrophy.
- Market Data Forecast. (2023). Gene therapy market size, growth, and forecast.
- IQVIA. (2023). U.S. prescription drug market analysis.
- Avalere Health. (2022). Payor negotiations and outcomes-based contracting in gene therapies.
- NICE. (2021). Cost-effectiveness of Zolgensma for SMA.
